Search Results

Generian Pharmaceuticals, Inc. announced that it has achieved the first research milestones for two programs in development under its collaboration agreement with Mitobridge, Inc.

OrsoBio, Inc. today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas Company.

Generian and Mitobridge, a wholly-owned subsidiary of Astellas Pharma, announced a collaboration to discover and develop novel small molecules for undruggable therapeutic targets.

By exercising the option right to acquire Mitobridge, Astellas paid $225M to acquire 100% of the equity in Mitobridge.

Generian Pharmaceuticals, Inc. (“Generian”) and Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma Inc. ) announced today that they have entered into a collaboration and exclusive license agreement to discover and develop novel small molecules for undruggable therapeutic targets by using a proprietary drug discovery platform for diseases that have limited treatment options.

The data demonstrated that Mitobridge’s proprietary compound MA-0217 corrects the mitochondrial deficits and alleviates the renal dysfunction in a rat ischemia reperfusion AKI model.

OcuSciences today announced the addition of Michael Patane, PhD, to its Board of Directors.